

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Pharmacy Compounding Advisory Committee (PCAC) Meeting
July 23-24, 2026

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Takyiah Stevenson, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

PHARMACY COMPOUNDING ADVISORY COMMITTEE MEMBERS (Voting)

Gabriel Alizaidy, MD, MS

Scientific Director
Maximus Health
Coralville, Iowa

Timothy D. Fensky, RPh, DPh, FACA

*(National Association of Boards of Pharmacy
Representative)*
President/Principal Consultant
Pharmacy Insights
Marlborough, Massachusetts

Melissa Loseke, DO

Chief Medical Officer
Re-new Institute
Omaha, Nebraska

David Pope, PharmD

Chief Pharmacy Officer
Xifin Pharmacy Solutions
Augusta, Georgia

Brian Serumaga, PhD

*(Acting Chairperson; United States
Pharmacopeia Representative)*
Director, Healthcare Quality and Safety Standards
United States Pharmacopoeia Convention
Rockville, Maryland

Asare B. Christian, MD, MPH, APBMR, ABAARM

Founder
Aether Medicine
Philadelphia, Pennsylvania

Senator Bobby Harshbarger, PharmD, FACA

Tennessee State Senator, District 4
Pharmacist
Premier Pharmacy Inc
Kingsport, Tennessee

Haleem Mohammed, MD, MBA

*(BPC-157, KPV, TB-500, MOTs-C and Semax-related
bulk drug substances (BDSs) Topics Only)*
Diplomate of the American Board of Internal Medicine
Global Chief Medical Officer, Gameday Health
Miami Beach, Florida

Elizabeth Rebello, MD, FACHE, FASA, CPPS,

CMQ *(BPC-157, KPV, TB-500, MOTs-C, Emideltide,
and Epitalon-related BDSs Topics Only)*
Professor
Executive Director, Anesthesiology, Critical Care and
Pain Medicine, Cancer Network
Department of Anesthesiology and Perioperative
Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Joshua Starbuck, MD

Chief Medical Officer
Makena Health
Wailea, Hawaii

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Pharmacy Compounding Advisory Committee (PCAC) Meeting
July 23-24, 2026

DRAFT MEETING ROSTER (cont.)

PHARMACY COMPOUNDING ADVISORY COMMITTEE MEMBERS (Voting) (cont.)

Kris H. Wusterhausen, DO

Founder and Medical Director
The Resurge Clinic
Weatherford, Texas

PHARMACY COMPOUNDING ADVISORY COMMITTEE MEMBERS (Non-Voting)

Donnette D. Staas, PhD

(Industry Representative)
Vice President, Regulatory Strategy
Jazz Pharmaceuticals
Philadelphia, Pennsylvania

TEMPORARY MEMBERS (Voting)

Todd Durham, PhD

(Consumer Representative)
Senior Vice President, Clinical & Outcomes
Research
Foundation Fighting Blindness
Columbia, Maryland

Brian P. Lee, MD, MAS

*(via video conferencing platform;
BPC-157-related BDSs Topic Only)*
Associate Professor of Medicine
Division of Gastrointestinal and Liver Diseases
Keck School of Medicine of USC
Los Angeles, California

Friedhelm Sandbrink, MD

(Semax-related BDSs Topic Only)
National Program Director for Pain Management
Specialty Care Services
Veteran's Health Administration
Director for Pain Management Program
Department of Neurology
Washington Veterans Affairs Medical Center
Washington, District of Columbia

Costantino Iadecola, MD

(Semax-related BDSs Topic Only)
Anne Parrish Titzell Professor of Neurology
Director and Chair
Feil Family Brain and Mind Research Institute
Weill Cornell Medicine
New York, New York

Josh Mailman MBA, FSNMMI

(Patient Representative)
President, NorCal CarciNET Community
President, Board of Directors Neuroendocrine
Tumor Research Foundation
Oakland, California

Maral Kibarian Skelsey, MD, FAAD, FACMS

(KPV and TB-500-related BDSs Topics Only)
Director
Dermatologic Surgery Center of Washington
Chevy Chase, Maryland
Clinical Professor, Department of Dermatology
Georgetown University School of Medicine
Washington, District of Columbia

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Pharmacy Compounding Advisory Committee (PCAC) Meeting
July 23-24, 2026

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Kevin L. Zacharoff, MD, FACIP, FACPE, FAAP

(Emideltide-related BDSs Topic Only)

Clinical Assistant Professor and Course Director of
Pain and Addiction

Distinguished Visting Scholar in Medical
Humanities, Compassionate Care, and Bioethics
Renaissance School of Medicine at Stony Brook
University
Stony Brook, New York

William C. Zamboni, PharmD, PhD

Director, Cancer Pharmacokinetics and
Pharmacodynamics Facility

Co-Leader, Immunotherapy and
Drug Development Center

University of Pittsburgh Medical Center Hillman
Cancer Center

Professor

Department of Pharmaceutical Sciences
University of Pittsburgh School of Pharmacy
Pittsburgh, Pennsylvania

FDA PARTICIPANTS (Non-Voting)

Matthew Lash, JD

Acting Director

Office of Compounding Quality
and Compliance (OCQC)

Office of Compliance (OC), CDER, FDA

Ian F. Deveau, PhD

Deputy Director

OCQC, OC, CDER, FDA

Dorcas (Ann) Taylor, PharmD, JD

Division III Director, Regulatory Counsel
OCQC, OC, CDER, FDA

Mary Than Hai, MD

(July 24, 2026 Sessions Only)

Director

Office of New Drugs (OND), CDER, FDA

Gautam Mehta, MD, MS

(July 23, 2026 Sessions Only)

Deputy Director for Clinical Science
OND, CDER, FDA

Suhail Kasim, MD, MPH

Lead Physician

Pharmacy Compounding Review Team (PCRT)

Office of Specialty Medicine (OSM)

OND, CDER, FDA

Kemi Asante, PharmD, MPH, RAC

Acting Branch Chief for Branch 7

OCQC, OC, CDER, FDA

Tracy Rupp, PharmD, MPH, BCPS, RD *(via
video conferencing platform)*

Lead Consumer Safety Officer

OCQC, OC, CDER, FDA

Russell Wesdyk, BS, MBA

Associate Director for Regulatory Affairs

Office of Product Quality Assessment II (OPQAI)

Office of Pharmaceutical Quality (OPQ)

CDER, FDA

Elizabeth Hankla, PharmD

(BPC-157-related BDSs Topic Only)

Senior Clinical Analyst

PCRT, OSM, OND, CDER, FDA

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Pharmacy Compounding Advisory Committee (PCAC) Meeting
July 23-24, 2026

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting) (cont.)

Marianne San Antonio, DO

(MOTS-c-related BDSs and Semax-related BDSs Topics Only)

Physician

PCRT, OSM, OND, CDER, FDA

Katie Park, PharmD, MPH

(Emideltide-related BDSs and Epitalon-related BDSs Topics Only)

Clinical Analyst

PCRT, OSM, OND, CDER, FDA

Mai Tu, PhD

(BPC-157-related BDSs Topic Only)

Senior Pharmaceutical Scientist

OPQAII, OPQ, CDER, FDA

Hong Ding, PhD

(Emideltide-related BDSs Topic Only)

Regulatory Scientific Reviewer

OPQAII, OPQ, CDER, FDA

Jamiele Mattocks, PharmD

(Emideltide-related BDSs and Semax-related BDSs Topics Only)

Consumer Safety Officer

OCQC, OC, CDER, FDA

Nga-Lai Poon, PharmD

(KPV-related BDSs and MOTS-c-related BDSs Topics Only)

Regulatory Specialist

OCQC, OC, CDER, FDA

Emily Kneeream, PharmD

(KPV-related BDSs and TB-500-related BDSs Topics Only)

Clinical Analyst

PCRT, OSM, OND, CDER, FDA

Jing Li, PhD

(KPV-related BDSs, MOTS-c-related BDSs, and Semax-related BDSs Topics Only)

Regulatory Scientific Reviewer

OPQAII, OPQ, CDER, FDA

Bini Mathew, MD

(TB-500-related BDSs Topic Only)

Pharmaceutical Scientist

OPQAII, OPQ, CDER, FDA

Nathaniel Iloanusi, PhD, RPH

(Epitalon-related BDSs Topic Only)

Regulatory Scientific Reviewer

OPQAII, OPQ, CDER, FDA

Ashlee Mattingly, PharmD, MPH

(TB-500-related BDSs and Epitalon-related BDSs Topics Only)

Consumer Safety Officer

OCQC, OC, CDER, FDA

Olubukola Adeyemi, PharmD, BCPS

(BPC-157-related BDSs Topic Only)

Consumer Safety Officer

OCQC, OC, CDER, FDA